Overview of Dr. Salles
Dr. Gilles Salles is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Université Claude Bernard Lyon and has been in practice 32 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
- Université Claude Bernard LyonClass of 1989
Certifications & Licensure
- NY State Medical License 2021 - 2025
Clinical Trials
- A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma Start of enrollment: 2021 May 04
Roles: Contact
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders Start of enrollment: 2000 Jul 01
Roles: Contact
- A Study of Mosunetuzumab in People With Follicular Lymphoma Start of enrollment: 2022 May 27
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Dynamics of Immune Reconstitution and Impact on Outcomes Across CAR-T Cell Products in Large B-Cell Lymphoma.Danny Luan, Susan DeWolf, Teng Fei, Sandeep Raj, Gunjan L Shah
Blood Cancer Discovery. 2024-12-12 - Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2024-12-11 - A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin, Anita Kumar, Matthew Matasar
Leukemia & Lymphoma. 2024-12-01
Press Mentions
- DLBCL: Polatuzumab Vedotin Enhances Progression-Free SurvivalDecember 17th, 2021
- DLBCL: PFS but No OS Benefit with Polatuzumab-Vedotin Add-OnDecember 17th, 2021
- Incyte : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCLJune 9th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: